AR082136A1 - Derivados heterociclicos fusionados como moduladores s1p - Google Patents

Derivados heterociclicos fusionados como moduladores s1p

Info

Publication number
AR082136A1
AR082136A1 ARP110102455A ARP110102455A AR082136A1 AR 082136 A1 AR082136 A1 AR 082136A1 AR P110102455 A ARP110102455 A AR P110102455A AR P110102455 A ARP110102455 A AR P110102455A AR 082136 A1 AR082136 A1 AR 082136A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
halogen
substituted
atoms
Prior art date
Application number
ARP110102455A
Other languages
English (en)
Inventor
Pieter Smid
Bakker Wouter I Iwema
Hein K A C Coolen
Leonardus A J M Sliedregt
Dongen Maria J P Van
Hartog Jacobus A J Den
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44358260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082136(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of AR082136A1 publication Critical patent/AR082136A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Los compuestos de la presente tienen afinidad con los receptores S1P y se puedan utilizar en el tratamiento, alivio o prevención de enfermedades y afecciones en las que (cualquier) receptor(es) S1P está(están) involucrados o en las que está involucrada la modulación del sistema de señalización S1P endógeno a través de cualquier receptor S1P.Reivindicación 1: Un derivado heterocíclico fusionado de la fórmula (1) en donde R1 se selecciona de ciano; alquenilo C2-4, alquinilo C2-4, alquilo C1-4, cada uno opcionalmente sustituido con CN o uno o más átomos de flúor; cicloalquilo C3-6, cicloalquenilo C4-6 o un grupo bicíclico C8-10, cada uno opcionalmente sustituido con halógeno o alquilo C1-4 opcionalmente sustituido con uno o más átomos de flúor; fenilo, bifenilo, naftilo, cada uno opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, ciano, alquilo C1-4 opcionalmente sustituido con uno o más átomos de flúor, alcoxi C1-4 opcionalmente sustituido con uno o más átomos de flúor, amino, dimetilamino, y cicloalquilo C3-6 opcionalmente sustituido con fenilo que se puede sustituir con alquilo C1-4 o halógeno; y fenilo sustituido con fenoxi, bencilo, benciloxi, feniletilo o heterociclo monocíclico, cada uno opcionalmente sustituido con alquilo C1-4; Z es un grupo de enlace -W-(alquileno Cn)-T- en donde W se adhiere a R1 y se selecciona de un enlace, -O-, -CO-, -S-, -SO-, -SO2-, -NH-, -CH=CH-, -C(CF3)=CH-, -CºC-, -CH2-O-, -O-CO-, - CO-O-, -CO-NH-, -NH-CO- y trans-ciclopropileno; n es un entero de 0 a 10; y T se adhiere al grupo funcional fenileno/ piridilo y se selecciona de un enlace, -O-, -S-, -SO-, -SO2-, -NH-, -CO-, -C=C-, -CºC-, y trans-ciclopropileno; R2 es H o uno o más sustituyentes seleccionados independientemente de ciano, halógeno, alquilo C1-4 opcionalmente sustituido con uno o más átomos de halógeno, o alcoxi C1-4 opcionalmente sustituido con uno o más átomos de halógeno; la estructura del anillo A puede contener un átomo de nitrógeno; X se selecciona de C o N; si X es C, R3 se selecciona de H y alquilo C1-4, de otra forma R3 no está presente; Y se selecciona de NH, O y S; la estructura Q es una amina cíclica de 5, 6 ó 7 miembros; y R4 es alquileno C1-4-R5 en donde uno o más átomos de carbono en el grupo alquileno se pueden sustituir independientemente con uno o más átomos de halógeno o con (CH2)2 para formar un grupo funcional ciclopropilo, o R4 es cicloalquileno C3-6-R5, -CH2-cicloalquileno C3-6-R5, cicloalquileno C3-6-CH2-R5 o -CO-CH2-R5, en donde R5 es -OH, -PO3H2, -OPO3H2, -COOH, -COO-alquilo C1-4 o tetrazol-5-ilo; o una sal farmacéuticamente aceptable, un solvato o hidrato del mismo o uno o más N-óxidos del mismo.
ARP110102455A 2010-07-09 2011-07-08 Derivados heterociclicos fusionados como moduladores s1p AR082136A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10169107 2010-07-09
EP11156007 2011-02-25

Publications (1)

Publication Number Publication Date
AR082136A1 true AR082136A1 (es) 2012-11-14

Family

ID=44358260

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102455A AR082136A1 (es) 2010-07-09 2011-07-08 Derivados heterociclicos fusionados como moduladores s1p

Country Status (27)

Country Link
US (3) US8796262B2 (es)
EP (1) EP2590980B1 (es)
JP (1) JP5973429B2 (es)
KR (1) KR101889694B1 (es)
CN (1) CN103068827B (es)
AR (1) AR082136A1 (es)
AU (1) AU2011275755B2 (es)
BR (1) BR112013000627B1 (es)
CA (1) CA2804137C (es)
CL (1) CL2013000069A1 (es)
CO (1) CO6670577A2 (es)
CR (1) CR20130056A (es)
DO (1) DOP2013000009A (es)
EC (1) ECSP13012416A (es)
ES (1) ES2653682T3 (es)
HK (1) HK1179956A1 (es)
IL (1) IL224054A (es)
MX (1) MX2013000360A (es)
MY (1) MY161229A (es)
NZ (1) NZ605491A (es)
PE (1) PE20130592A1 (es)
RU (1) RU2576660C2 (es)
SG (1) SG186952A1 (es)
TW (1) TWI522361B (es)
UY (1) UY33496A (es)
WO (1) WO2012004373A1 (es)
ZA (1) ZA201300157B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
USRE48301E1 (en) 2010-07-09 2020-11-10 Abbvie B.V. Fused heterocyclic derivatives as S1P modulators
JP2016011257A (ja) * 2012-10-23 2016-01-21 大日本住友製薬株式会社 テトラヒドロオキサゾロピリジン誘導体
WO2017036978A1 (en) * 2015-08-28 2017-03-09 Abbvie Inc. Fused heterocyclic compounds as s1p modulators
EP3535244A1 (en) 2016-11-02 2019-09-11 Abbvie Deutschland GmbH & Co. KG Spiro-compounds as s1p modulators
AU2020373047A1 (en) 2019-10-31 2022-05-19 ESCAPE Bio, Inc. Solid forms of an S1P-receptor modulator
BR112022008137A2 (pt) * 2019-10-31 2022-07-19 Escape Bio Inc Processos para preparar um modulador de receptor s1p
EP4116294A1 (en) 2020-03-04 2023-01-11 Helioeast Pharmaceutical Co., Ltd. Benzo 2-azaspiro[4.4]nonane compound and use thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1069387A1 (ru) 1982-07-01 1985-11-30 Институт физико-органической химии и углехимии АН УССР Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием
GB2228432A (en) 1989-01-13 1990-08-29 Grayston Central Services Multi-role machine for heating and coating pipe welds.
JPH03206042A (ja) * 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
JP2681589B2 (ja) 1992-12-28 1997-11-26 日揮株式会社 配管溶接継手の熱処理方法
JPH072848A (ja) 1993-04-23 1995-01-06 Sankyo Co Ltd モルホリンおよびチオモルホリン誘導体
GB9522845D0 (en) 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
JP3822680B2 (ja) 1996-08-30 2006-09-20 新日本製鐵株式会社 誘導加熱された接合部の冷却方法および冷却装置
RU2275371C2 (ru) 2000-04-21 2006-04-27 Шионоги Энд Ко., Лтд. Производные оксадиазола, обладающие противоопухолевым действием, лекарственное средство, их содержащее, и способ лечения
FR2822727A1 (fr) 2001-04-03 2002-10-04 Gesal Ind Procede d'application d'un revetement resistant aux hautes temperatures, dispositif pour la mise en oeuvre de ce procede et objet pourvu dudit revetement
JP3649223B2 (ja) 2003-01-08 2005-05-18 株式会社日立製作所 配管系の熱処理方法および熱処理装置
JP4564952B2 (ja) * 2003-01-17 2010-10-20 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
JP4648899B2 (ja) 2003-06-12 2011-03-09 ビーティージー・インターナショナル・リミテッド 神経賦活性化合物としての環式ヒドロキシルアミン
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CA2564994A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
GB0409744D0 (en) 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
UA88786C2 (ru) * 2004-06-30 2009-11-25 Атерсис, Инк. Производные замещенного азепина как модуляторы рецептора серотонина
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
JP4491334B2 (ja) 2004-12-01 2010-06-30 日立Ｇｅニュークリア・エナジー株式会社 配管の熱処理方法および装置
JP4599250B2 (ja) 2005-08-10 2010-12-15 株式会社東芝 高周波誘導加熱時外面温度制御方法および当該制御装置
JP2007063642A (ja) 2005-09-01 2007-03-15 Hitachi Ltd 残留応力改善方法と高周波誘導加熱用コイル
GB0520164D0 (en) * 2005-10-04 2005-11-09 Novartis Ag Organic compounds
CN101356178A (zh) * 2006-01-30 2009-01-28 Irm责任有限公司 作为ppar调节剂的化合物和组合物
JP2009528363A (ja) 2006-02-28 2009-08-06 ヘリコン セラピューティクス，インコーポレイテッド Ｐｄｅ４インヒビターとしての治療用ピペラジン
WO2007109334A2 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. Sip receptor modulating compounds and use thereof
EP2049548A1 (en) 2006-07-27 2009-04-22 UCB Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
JP2010502675A (ja) 2006-09-08 2010-01-28 ノバルティス アクチエンゲゼルシャフト リンパ球相互作用が介在する疾患または障害を処置するために有用なｎ−ビアリール（ヘテロ）アリールスルホンアミド誘導体
BRPI0720478A2 (pt) 2006-12-21 2014-01-14 Abbott Laboratoires Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato
CN101668741A (zh) * 2007-01-11 2010-03-10 阿勒根公司 具有鞘氨醇-1-磷酸(s1p)受体拮抗剂生物学活性的6-取代吲哚-3-羧酸酰胺化合物
MX2009011421A (es) 2007-04-23 2009-12-15 Novartis Ag Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p.
WO2009084501A1 (ja) * 2007-12-27 2009-07-09 Asahi Kasei Pharma Corporation スルタム誘導体
CA2710474A1 (en) * 2008-01-24 2009-07-30 Ucb Pharma, S.A. Compounds comprising a cyclobutoxy group
WO2009097567A1 (en) 2008-01-30 2009-08-06 Cephalon, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
UA100877C2 (ru) 2008-01-30 2013-02-11 Сефалон, Інк. Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3)
US20090321144A1 (en) 2008-06-30 2009-12-31 Wyble Kevin J Protecting an element from excessive surface wear by localized hardening
UY32858A (es) 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
US9051275B2 (en) 2010-02-04 2015-06-09 Laboratories Del Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
CN101812058B (zh) 2010-04-13 2012-03-21 湖南大学 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用
TW201206893A (en) * 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators

Also Published As

Publication number Publication date
IL224054A (en) 2016-07-31
KR101889694B1 (ko) 2018-08-21
US20150284403A1 (en) 2015-10-08
ES2653682T3 (es) 2018-02-08
JP5973429B2 (ja) 2016-08-23
EP2590980B1 (en) 2017-09-20
CO6670577A2 (es) 2013-05-15
CN103068827A (zh) 2013-04-24
CA2804137A1 (en) 2012-01-12
MX2013000360A (es) 2013-06-28
UY33496A (es) 2012-01-31
RU2576660C2 (ru) 2016-03-10
JP2013531002A (ja) 2013-08-01
BR112013000627A2 (pt) 2016-05-24
TW201206945A (en) 2012-02-16
CL2013000069A1 (es) 2013-06-07
AU2011275755A8 (en) 2013-02-14
PE20130592A1 (es) 2013-05-22
AU2011275755B2 (en) 2015-04-09
US9096612B2 (en) 2015-08-04
MY161229A (en) 2017-04-14
KR20140005849A (ko) 2014-01-15
AU2011275755A1 (en) 2013-01-31
US20140066433A1 (en) 2014-03-06
CR20130056A (es) 2013-06-12
US9670220B2 (en) 2017-06-06
ECSP13012416A (es) 2013-03-28
NZ605491A (en) 2014-08-29
US20130203737A1 (en) 2013-08-08
HK1179956A1 (zh) 2013-10-11
SG186952A1 (en) 2013-02-28
RU2013105444A (ru) 2014-08-20
TWI522361B (zh) 2016-02-21
EP2590980A1 (en) 2013-05-15
WO2012004373A1 (en) 2012-01-12
ZA201300157B (en) 2017-05-31
BR112013000627B1 (pt) 2020-12-08
DOP2013000009A (es) 2013-10-15
CN103068827B (zh) 2016-05-04
US8796262B2 (en) 2014-08-05
CA2804137C (en) 2019-06-11

Similar Documents

Publication Publication Date Title
AR082136A1 (es) Derivados heterociclicos fusionados como moduladores s1p
AR082135A1 (es) Derivados de espiro-piperidina como moduladores s1p
RU2345996C1 (ru) Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
AR081390A1 (es) Compuestos de morfolina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el antagonismo del receptor mineralocorticoide (mra)
AR077849A2 (es) Compuestos y composiciones como inhibidores de proteina quinasa
AR106037A1 (es) Moduladores de la proteína core de la hepatitis b
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR102094A1 (es) Inhibidores de proteínas kras con una mutación g12c
MX2011011875A (es) Compuesto de carboxamida heterociclica diamino.
AR078609A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros.
AR085149A1 (es) Moduladores del receptor de glucagon
BR112015015812A2 (pt) derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
EA200501326A1 (ru) Пиримидины и триазины, ингибирующие репликацию вич
AR074089A1 (es) Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
ECSP10010414A (es) Compuestos tricíclicos que tienen actividad antagonista de factor de liberación de corticotropina y composiciones farmacéuticas que contienen los mismos
AR065333A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
AR077969A1 (es) Derivados de (tio)morfolina comomoduladores de s1p
AR087487A1 (es) Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak)
EA201301334A1 (ru) Меченные радиоактивными изотопами ингибиторы глутаминилциклазы
MX2016003422A (es) Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
AR066576A1 (es) Nuevos derivados de pirazolona

Legal Events

Date Code Title Description
FG Grant, registration